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Edited by Mike ShipstonPolyamines, such as putrescine, spermidine, and spermine,
are physiologically important polycations, but the transporters
responsible for their uptake in mammalian cells remain poorly
characterized. Here, we reveal a new component of the
mammalian polyamine transport system using CHO-MG cells,
a widely used model to study alternative polyamine uptake
routes and characterize polyamine transport inhibitors for
therapy. CHO-MG cells present polyamine uptake deficiency
and resistance to a toxic polyamine biosynthesis inhibitor
methylglyoxal bis-(guanylhydrazone) (MGBG), but the molec-
ular defects responsible for these cellular characteristics
remain unknown. By genome sequencing of CHO-MG cells, we
identified mutations in an unexplored gene, ATP13A3, and
found disturbed mRNA and protein expression. ATP13A3
encodes for an orphan P5B-ATPase (ATP13A3), a P-type
transport ATPase that represents a candidate polyamine
transporter. Interestingly, ATP13A3 complemented the
putrescine transport deficiency and MGBG resistance of CHO-
MG cells, whereas its knockdown in WT cells induced a CHO-
MG phenotype demonstrated as a decrease in putrescine up-
take and MGBG sensitivity. Taken together, our findings
identify ATP13A3, which has been previously genetically
linked with pulmonary arterial hypertension, as a major
component of the mammalian polyamine transport system that
confers sensitivity to MGBG.
The polyamines, putrescine (PUT), spermidine (SPD), and
spermine (SPM), are abundant aliphatic polycations that
are required for various cell functions including prolifera-
tion, differentiation, apoptosis, protein post-translationalThis article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).modifications, and ion channel regulation (1, 2). Polyamines
provide cardioprotection and extend life span in several model
organisms (3, 4), whereas excessive concentrations of poly-
amines induce cellular toxicity, possibly through the formation
of toxic metabolites (5). Therefore, the cellular polyamine
homeostasis is tightly controlled by fine-tuning polyamine
biosynthesis, degradation, export, and cellular uptake of
exogenous polyamines via the polyamine transport system
(PTS) (2).
Polyamine synthesis starts from ornithine that is converted
to PUT by ornithine decarboxylase, followed by PUT meta-
bolism to SPD and SPM via SPD and SPM synthase, respec-
tively (Fig. S1) (2). This pathway is strictly regulated mainly
through controlling the levels and activity of the rate-limiting
enzyme ornithine decarboxylase via antizyme and antizyme
inhibitor (Fig. S1) (6). Polyamine synthesis can also be pre-
vented by synthetic blockers such as difluoromethylornithine
(DFMO), a selective inhibitor of ornithine decarboxylase, or
methylglyoxal bis-(guanylhydrazone) (MGBG), an SPD analog
that inhibits the formation of decarboxylated S-adenosylme-
thionine, a precursor of SPD and SPM (Fig. S1) (7). Inhibition
of polyamine synthesis by DFMO leads to an increased cellular
polyamine uptake (8–10) and increased ornithine decarbox-
ylase and S-adenosylmethionine decarboxylase synthesis (8),
indicating that polyamine production and uptake exert com-
plementary functions.
So far, the mechanism of cellular polyamine uptake and the
identity of the mammalian PTS remain largely unknown
(6, 9, 11) although polyamine transporters represent inter-
esting cancer targets (12). One of the best-studied models used
to characterize the mammalian PTS includes a mutant Chinese
hamster ovary (CHO) cell line that was generated by random
mutagenesis followed by selection for MGBG resistance
(hence named CHO-MG) (13). These cells exhibit a distinct
phenotype manifested by an impaired polyamine uptake and aJ. Biol. Chem. (2021) 296 100182 1
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ATP13A3 is involved in polyamine transportbetter survival against MGBG toxicity due to a reduced cellular
uptake of MGBG (14). The cell model has been extensively
used to study pathways of the enigmatic mammalian PTS
(13–18) and to test polyamine transport inhibitors for therapy
(19–22). However, despite serious efforts, the defective poly-
amine transporter(s) in the CHO-MG model remain(s) to be
identified.
Based on studies in CHO-MG cells and other models,
several polyamine transport routes have been proposed to
account for experimental observations of cellular polyamine
uptake, but a unifying theory is lacking, presumably because of
the existence of multiple parallel systems (12). Potential
plasma membrane polyamine transporters include the solute
carrier transporter, SLC3A2, with PUT selectivity (23, 24). An
alternative pathway involves the endocytic internalization of
extracellular polyamines via heparan sulfate groups of plasma
membrane proteins called glypicans (25, 26). Also, a vesicular
SLC18B1 importer has been reported presenting SPD and
SPM selectivity (27). Recently, we characterized the ubiquitous
P5B-ATPase, ATP13A2, as a polyamine transporter in the
late endosomal/lysosomal compartment that preferentially
sequesters SPM and SPD out of the late endosomal/lysosomal
lumen into the cytosol (28). ATP13A2 removes polyamines
from the lysosome, which benefits lysosomal health and
functionality. This process is compatible with the glypican-
dependent endosomal uptake route that contributes to the
cellular uptake of polyamines complementing the polyamine
synthesis in the cytosol. ATP13A2 may mediate cellular
polyamine uptake via a two-step mechanism involving cellular
entry of polyamines through endocytosis, followed by
sequestration of polyamines out of the late endosomal/
lysosomes by ATP13A2 (28). It remains unknown whether the
other orphan P5B-ATPases, ATP13A3-5, may also be poly-
amine transporters of the mammalian PTS (29).
We, therefore, hypothesized that the underlying molecular
defect of the CHO-MG phenotype might be due to a
dysfunction of one or more members of the P5B-ATPases. In
CHO-MG cells, we identified mutations in the coding
sequence of the ATP13A3 gene, which encodes for a P5B-
ATPase expressed in the early and recycling endosomes
(29). We demonstrated ATP13A3 expression deficiency at
both the mRNA and protein levels. Importantly, reintro-
ducing WT ATP13A3 restores the polyamine uptake and
MGBG resistance phenotype of CHO-MG cells, whereas
ATP13A3 knockdown in WT cells induces these phenotypes.
Therefore, ATP13A3 represents a novel member of the
mammalian PTS.Results
CHO-MG cells exhibit MGBG resistance and impaired
BODIPY–PUT uptake
First, we confirmed via viability assays the resistance of
CHO-MG cells against MGBG-induced toxicity as compared
with CHO control cells (CHO-WT) (Fig. 1A) (9, 13, 14).
Furthermore, we verified whether the PTS was defective in the
CHO-MG cell line. We assessed the cellular polyamine uptake2 J. Biol. Chem. (2021) 296 100182capacity using boron dipyrromethene (BODIPY)-conjugated
SPD and SPM (Fig. 1B) that are taken up by the PTS (30) and
transported by ATP13A2 (28), but both CHO cell lines
exhibited similar levels of BODIPY–SPD and BODIPY–SPM
uptake (Fig. 1B). Also, CHO-WT and CHO-MG models
were equally sensitive to the toxicity of high SPD and SPM
concentrations (Fig. S2). Because no obvious SPD or SPM
phenotype was observed in CHO-MG, we next evaluated PUT
uptake and toxicity. We, therefore, synthesized BODIPY-
labeled PUT for this study and observed that its uptake was
approximately 5-fold lower in CHO-MG than in CHO-WT
(Fig. 1B), confirming a defective PTS in CHO-MG. Benzyl
viologen (BV), a known inhibitor of the PTS (31), blocked
BODIPY–PUT uptake in CHO-WT to the levels observed in
CHO-MG cells (Fig. 1B). We then investigated the effect of
increasing concentrations of exogenous PUT on the toxicity of
50-μM MGBG, a concentration that caused a significant
reduction in CHO-WT viability, as previously shown in
Figure 1A. Supplementation of PUT on itself did not induce
toxicity in either of the two CHO models (Fig. 1C), in line with
previous observations (28), whereas PUT reduced MGBG
toxicity in CHO-WT in a dose-dependent manner reaching
complete prevention at 1-mM PUT (Fig. 1C). Because MGBG
is taken up by the PTS (7, 13, 14), our results point to a
competition between PUT and MGBG uptake via the same
transport system.
Overall, CHO-MG cells are resistant to MGBG and present
a reduced BODIPY–PUT uptake capacity, which may relate to
a defective polyamine transporter of MGBG and PUT.
ATP13A3 deficiency in CHO-MG cells
Based on the recent discovery that ATP13A2 is a polyamine
transporter that regulates the cellular polyamine content (28),
we hypothesized that ATP13A2, or one of the other related
P5-type orphan transporters such as ATP13A1 (a P5A-
ATPase) or ATP13A3-5 (P5B-ATPases) (29), may be impli-
cated in the CHO-MG phenotype. The Chinese hamster
(Cricetulus griseus) genome does not contain an ATP13A5
gene (32), so we compared the relative mRNA expression
levels of the P5A-ATPase, ATP13A1, and the P5B-ATPases,
ATP13A2-4, between CHO-WT and CHO-MG via quantita-
tive RT-PCR (Fig. 2A), for which the primer sets were validated
(Fig. S3A). Whereas the relative mRNA levels of ATP13A1 and
ATP13A2 were not significantly different, ATP13A3 mRNA
was significantly decreased in CHO-MG compared with CHO-
WT cells (Fig. 2A). Importantly, we confirmed the decreased
expression of ATP13A3 in CHO-MG cells at the protein level
via proteomic analysis (Fig. 2B and Fig. S3B). ATP13A4
mRNA expression was hardly detected in the CHO models
although the ATP13A4 primers were validated with cDNA
derived from hamster brain, the tissue that shows the highest
ATP13A4 expression in mice (33) (Fig. S3C). The low
ATP13A4 expression in CHO cells is in line with the poor
ATP13A4 expression in human ovaries (34).
As CHO-MG cells were generated by random mutagenesis
(13), we analyzed the DNA sequence of the CHO-MG
ATP13A3 gene. Genome sequencing revealed 54 DNA
Figure 1. CHO-MG cells exhibit MGBG resistance and impaired BODIPY–PUT uptake. A and C, cells were treated for 24 h with the indicated con-
centrations of MGBG alone (A), or PUT with or without 50-μM MGBG (C). CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) was used to assess
cell viability and dose–response curves were plotted (n = 3). B, cells were treated with 5-μM BODIPY–polyamines for 90 min at 37 C with or without 90 min
of 1-mM BV pretreatment to inhibit polyamine uptake. Uptake was measured in terms of the mean fluorescence intensity (MFI) up to 1 × 104 events (debris
free) per condition on the flow cytometer (n = 3). Data represent the mean ± SEM (A and C) or mean ± SD (B), and individual data points (representing
replicates) are overlaid on bar graph plots (€p < 0.05, ****/€€€€p < 0.0001, **** versus CHO-WT(+MGBG), €€€€ versus CHO-MG(+MGBG)). Analyses were
performed using two-way ANOVA and Bonferroni post hoc corrections. BODIPY, boron dipyrromethene; BV, benzyl viologen; MGBG, methylglyoxal bis-
(guanyl hydrazone); SPD, spermidine; SPM, spermine; PUT, putrescine.
ATP13A3 is involved in polyamine transportmutations in the CHO-MG ATP13A3 gene as compared with
the reference CHO genome (RefSeq Assembly
GCF_000223135.1). Only two of the 54 mutations were found
in the coding sequence and both of them were heterozygous.
The first coding sequence mutation is located on nucleotide
45284 of contig NW_003615339.1 (genotype = 0/1; read
depth for each allele = 21,33; read depth = 54; genotype
quality = 99; phred-scaled genotype likelihoods rounded to
the closest integer = 1216,0,715), leading to a nonsense
mutation at the protein level converting the Trp codon 511
(TGG) to a stop codon (TGA) (p.Trp511X) (Fig. 2C). The
second coding sequence mutation results in a frameshift at
the protein level at position 936 (p.Phe936Serfs25X)
(Fig. 2C). Here, nucleotide 57302 in contig NW_003615339.1
is deleted (genotype = 0/1; read depth for each allele = 25,27;
read depth = 52; genotype quality = 99; phred-scaled geno-
type likelihoods rounded to the closest integer = 855,0,777),
removing the first thymine in the Phe codon (TTC) at po-
sition 936 of the ATP13A3 protein sequence. Both mutations
in the coding sequence of ATP13A3 are compatible with the
decreased mRNA and protein expression of ATP13A3 in
CHO-MG cells.Impaired ATP13A3 transport activity underlies the CHO-MG
phenotype
Next, we verified whether the impaired ATP13A3 expres-
sion is responsible for the CHO-MG phenotype by restoring
ATP13A3 levels via lentiviral transduction. We generated
stable CHO-WT and CHO-MG cells expressing comparable
levels of humanWT (A3-WT) or a catalytically dead mutant of
ATP13A3 that is defective in the autophosphorylation activity
(D498N; A3-DN) and hence predicted to be transport deficient
(Fig. 3A) (29). Note that the ATP13A3 antibody fails to detect
a clear band in CHO-WT, indicating that the antibody may
react weaker with the endogenous hamster ATP13A3 protein
than with the overexpressed human ATP13A3 protein
(9 residues are different in the epitope region), and/or the
endogenous signal may be overshadowed by the relatively
higher overexpression in CHO-WT+A3-WT. Importantly,
compared with the nontransduced CHO-MG cells, there was a
significant increase in the uptake of BODIPY–PUT in CHO-
MG+A3-WT cells, comparable with the uptake level observed
in CHO-WT+A3-WT cells (Fig. 3B), demonstrating successful
recovery of BODIPY–PUT uptake. However, this rescue was
not observed in CHO-MG+A3-DN cells expressing theJ. Biol. Chem. (2021) 296 100182 3
Figure 2. ATP13A3 is downregulated in CHO-MG cells. A, ATP13A1-3 mRNA levels were measured with quantitative RT-PCR using SYBR Green master mix
(n = 4). B, protein expression of ATP13A3 was checked via proteomic analysis (n = 4). C, ATP13A3 topology model with the identified mutations in CHO-MG
cells. Data represent the mean ± SD (A and B) and individual data points (representing replicates) are overlaid on bar graph plots (**p < 0.01, ****p <
0.0001). Analyses were performed using one-way ANOVA and Bonferroni post hoc corrections (A) and unpaired t-test (B). A1-A3, ATP13A1-3; FKBPA1, FKBP
prolyl isomerase 1A.
ATP13A3 is involved in polyamine transportcatalytically dead ATP13A3 mutant (Fig. 3B), indicating that
the transport function of ATP13A3 was essential for the re-
covery of BODIPY–PUT uptake. Note that the uptake of
BODIPY–PUT in CHO-WT+A3-WT cells, exhibiting the
highest ATP13A3 expression, still falls within the linear range
(Fig. S4). The resistance to MGBG-induced toxicity was also
significantly reduced by 40% in CHO-MG+A3-WT cells as
compared with the nontransduced CHO-MG and CHO-
MG+A3-DN cell lines (Fig. 3C).
To further establish ATP13A3 dysfunction as a key
contributor in the CHO-MG phenotype, we induced stable
shRNA-mediated knockdown of ATP13A3 in the CHO-WT
background and checked if that would lead to a phenotype
comparable with CHO-MG cells. Via quantitative RT-PCR, we
observed a major reduction in ATP13A3 expression in two
independent knockdown models (Fig. 4A), which reduced the
uptake of BODIPY–PUT to the same level as in CHO-MG4 J. Biol. Chem. (2021) 296 100182cells (Fig. 4B) and significantly increased the resistance of
the cells against MGBG by 40% (Fig. 4C), in line with the
rescue results (Fig. 3C).
Together, the complementary data in the rescue and
knockdown cell models convincingly demonstrate that defec-
tive ATP13A3-mediated transport underlies the impaired
BODIPY–PUT uptake in CHO-MG cells and is at least
partially responsible for the MGBG resistance phenotype.ATP13A3-dependent transport presents broad polyamine
specificity
We examined the likely substrate specificity of ATP13A3-
dependent transport via cellular uptake experiments. Over-
expression of WT ATP13A3 in CHO-MG caused no signifi-
cant difference in the uptake of BODIPY–PUT, BODIPY–
SPD, and BODIPY–SPM as compared with CHO-WT+A3-
Figure 3. Expression of WT ATP13A3 restores the CHO-MG phenotype. A, stable cell lines were generated by lentiviral transduction to overexpress WT
(A3-WT) or a catalytically dead mutant (A3-DN) of ATP13A3. Expression of the viral vectors was verified by immunoblotting using an ATP13A3 selective
antibody, while the loading was monitored by a selective antibody of the house-keeping protein, GAPDH. B, cells were treated with 5-μM BODIPY–
polyamines for 90 min at 37 C with or without 90 min of 1-mM BV before treatment to inhibit polyamine uptake. Uptake was measured in terms of
the mean fluorescence intensity (MFI) up to 1 × 104 events (debris free) per condition on the flow cytometer (n = 5–9). C, cells were treated for 24 h with
different doses of MGBG. Cell viability was assessed using CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS), and dose–response curves were
plotted (n = 3). Data represent the mean ± SD (B) and individual data points (representing replicates) are overlaid on bar graph plots, or the mean ± SEM (C)
(****/€€€€p < 0.0001, ns = not significant, **** versus CHO-WT + A3-WT, €€€€ versus CHO-MG and CHO-MG + A3-DN). Analyses were performed using two-way
ANOVA and Bonferroni post hoc corrections. A3-DN, overexpression of ATP13A3 catalytically dead mutant D498N; A3-WT, overexpression of WT ATP13A3;
BODIPY, boron dipyrromethene; BV, benzyl viologen; MGBG, methylglyoxal bis-(guanyl hydrazone); PUT, putrescine.
ATP13A3 is involved in polyamine transportWT (Fig. 5A). Via competition assays, we observed that the
unlabeled PUT competed with BODIPY–PUT uptake in cells
expressing WT ATP13A3 (Fig. 5C), further confirming that
PUT is most likely a substrate transported through ATP13A3.
Interestingly, nonfluorescent SPD and SPM also competed
with the uptake of BODIPY–PUT in all cell lines with func-
tional ATP13A3, possibly hinting at a broad polyamine sub-
strate specificity (Fig. 5D). Moreover, MGBG showed
competition against BODIPY–PUT uptake in a dose-
dependent manner in CHO-WT+A3-WT and CHO-
MG+A3-WT (Fig. 5B), confirming that MGBG and BODIPY–
PUT follow the same uptake route via ATP13A3. Also, SPD
and SPM protected against MGBG toxicity in CHO-WT cells
(Fig. S5, A–B).
Next, we independently verified substrate specificity in
viability experiments with DFMO, an inhibitor of ornithine
decarboxylase, the rate-limiting step in polyamine synthesis.
Blocking endogenous polyamine synthesis by DFMO (Fig. S1)
makes cells more dependent on cellular uptake of polyamines
(9). Interestingly, ATP13A3 expression significantly reduced
DFMO toxicity in the CHO-MG background, mainly when
exogenous PUT was provided, and more mildly when SPD orSPM was administered (Fig. 5, E–G), demonstrating that poly-
amine uptake via ATP13A3 complements a lower ornithine
decarboxylase activity. Note that PUT exhibits no toxicity in the
concentration range we used, whereas SPD and SPM become
toxic at higher concentrations, which explains why ATP13A3
protection against DFMO fades at higher concentrations of SPD
and SPM (Fig. 5, E–G). Overall, our data indicate that
ATP13A3-dependent transport presents a broad specificity to
polyamines including PUT, SPD, and SPM, as well as MGBG.
Cellular uptake of BODIPY–PUT involves endocytosis
Because ATP13A3 localizes to the early and recycling
endosomes (29), we investigated whether endocytosis is
involved in the uptake of BODIPY–PUT by testing the ef-
fect of endocytosis inhibitors. Administration of a cocktail
of Dynasore, genistein, and Pitstop 2, which collectively
inhibits the clathrin-mediated, clathrin-independent, and
caveolin-mediated endocytic pathways (28), significantly
reduced BODIPY–PUT uptake in CHO-WT and CHO-
WT+A3-WT but not in CHO-MG cells (Fig. 6A), demon-
strating the contribution of endocytosis in the uptake pro-
cess. Also, we observed via confocal microscopy that theJ. Biol. Chem. (2021) 296 100182 5
Figure 4. Depletion of ATP13A3 in CHO-WT cells causes a CHO-MG phenotype. A, stable cell lines were generated by lentiviral transduction to knock
down ATP13A3 in CHO-WT cells. Efficiency of the knockdown was verified at the mRNA level with quantitative PCR (n = 3). B, cells were treated with 5-μM
BODIPY–polyamines for 90 min at 37 C with or without 90 min of 1-mM BV before treatment to inhibit polyamine uptake. Uptake was measured in terms of
the mean fluorescence intensity (MFI) up to 1 × 104 events (debris free) per condition on the flow cytometer (n = 3). C, cells were treated for 24 h with
different doses of MGBG. Cell viability was assessed using CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS), and dose–response curves were
plotted (n = 3). Data represent the mean ± SD (A and B) and individual data points (representing replicates) are overlaid on bar graph plots, or the mean ±
SEM (C) (*p < 0.05, **p < 0.01, ****/€€€€p < 0.0001, **** versus CHO-WT + A3-KD1, €€€€ versus CHO-WT + A3-KD2). Analyses were performed using two-way
ANOVA and Bonferroni post hoc corrections. A3, ATP13A3; A3-KD, knockdown of ATP13A3; BODIPY, boron dipyrromethene; BV, benzyl viologen; FKBPA1,
FKBP prolyl isomerase 1A; MGBG, methylglyoxal bis-(guanyl hydrazone); miR-fluc, expression of microRNA against firefly luciferase; PUT, putrescine.
ATP13A3 is involved in polyamine transportfluorescence intensity of BODIPY–PUT was significantly
higher and more widespread in CHO-WT than in CHO-MG
cells where the signal was confined to vesicular structures
(Fig. 6, C–D) that colocalized with various endosomal
markers (Fig. 6, E–F). These observations in CHO-MG cells
are in line with the impaired transport of endocytosed
BODIPY–PUT to the cytosol as a consequence of ATP13A3
dysfunction. We also checked whether the lower BODIPY–
PUT uptake in CHO-MG cells is not merely the result of
impaired endocytosis by measuring uptake of Alexa647-
transferrin (35) that is sensitive to the same endocytosis
inhibitor cocktail (Fig. 6B). Remarkably, we observed that
the endocytosis of Alexa647-transferrin in CHO-MG cells
was 5-fold higher than in CHO-WT (Fig. 6B), which is,
therefore, not responsible for the lower BODIPY–PUT up-
take levels observed in CHO-MG cells.
Although BV is a potent inhibitor of BODIPY–PUT
uptake (Fig. 6A), it had no effect on Alexa647-transferrin
uptake (Fig. 6B), indicating that BV may block another
stage of the BODIPY–PUT uptake route. Interestingly, BV6 J. Biol. Chem. (2021) 296 100182treatment led to a reduced uptake of BODIPY–PUT that
accumulates in vesicular structures, similar to the
BODIPY–PUT pattern in ATP13A3-deficient CHO-MG
cells (Fig. 6, C–D). This indicates that BV may inhibit
BODIPY–PUT uptake downstream of endocytosis, possibly
at the level of ATP13A3.
ATP13A2 and ATP13A3 fulfill overlapping functions in cellular
polyamine uptake
We recently reported that ATP13A2 is a polyamine trans-
porter with a higher affinity for SPM and SPD than PUT,
which stimulates the uptake of BODIPY–SPM and BODIPY–
SPD in cells, regulates the endogenous polyamine content, and
complements DFMO toxicity (28). Also, ATP13A2 deficiency
causes increased sensitivity to exogenous SPD or SPM because
of lysosomal stress (28). We, therefore, examined whether
ATP13A2 may also play a role in the CHO-MG phenotype.
However, in CHO-MG cells, the ATP13A2 mRNA levels were
not significantly altered (Fig. 2A), the uptake of BODIPY–SPD
and BODIPY–SPM was not reduced (Fig. 1B), and CHO-WT
Figure 5. ATP13A3-dependent transport exhibits a broad specificity toward PUT, SPD, and SPM. A–D, cells were treated with only 5-μM BODIPY–PUT,
BODIPY–SPD, or BODIPY–SPM (n = 4) (A), or with 5-μM BODIPY–PUT combined with different concentrations (1 μM, 5 μM, 10 μM, or 50 μM) of MGBG (n = 4)
(B), nonfluorescent PUT (n = 3–6) (C) or nonfluorescent SPD/SPM (n = 3) (D) for 90 min at 37 C. Uptake was measured in terms of the mean fluorescence
intensity (MFI) up to 1 × 104 events (debris free) per condition on the flow cytometer. E–G, cells were treated for 72 h with the indicated concentrations of
PUT (E), SPD (F), and SPM (G) combined with 1-mM DFMO. CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) was used to assess cell viability,
and dose–response curves were plotted (n = 3). Data represent the mean ± SD (A–D), and individual data points (representing replicates) are overlaid on bar
graph plots, or the mean ± SEM (E-G) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns = not significant). Analyses were performed using two-way
ANOVA and Bonferroni post hoc corrections. A3-DN, overexpression of ATP13A3 catalytically dead mutant D498N; A3-WT, overexpression of WT ATP13A3;
BODIPY, boron dipyrromethene; BV, benzyl viologen; DFMO, difluoromethylornithine; MGBG, methylglyoxal bis-(guanyl hydrazone); PUT, putrescine; SPD,
spermidine; SPM, spermine.
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Figure 6. BODIPY–PUT is taken up via endocytosis. A, cells were treated with 5-μM BODIPY–PUT for 90 min at 37 C with or without 30 min pretreatment
of 1-mM BV or endocytosis inhibitors (100-μM Dynasore, 50-μM genistein, and 50-μM Pitstop-2). Uptake was measured in terms of the mean fluorescence
intensity (MFI) up to 1 × 104 events (debris free) per condition on the flow cytometer (n = 3–4). B, cells were treated with BV or endocytosis inhibitors, while
being starved for 30 min. Afterward, they were incubated at 4 C for 15 min, treated with 50 μg/ml Alexa647-transferrin for 20 min, and incubated at 37 C,
5% CO2 for 15 min. Uptake was measured in terms of the mean fluorescence intensity (MFI) up to 1 × 10
4 events (debris-free) per condition on the
flow cytometer (n = 5). C and E, cells were treated with BODIPY–PUT for 90 min at 37 C with or without 30 min pretreatment of 1-mM BV and incubated
with primary antibodies for EEA1, RAB11, RAB7, and LAMP1 (1:200) followed by staining with Alexa Fluor 594 goat anti-rabbit antibody (1:1000) for 60 min
and the nuclear stain DAPI (200 ng/ml) for 15 min (n=3–5). Confocal microscopy images (scale bar = 20 μm; boxed areas are enlarged in the inset with scale
ATP13A3 is involved in polyamine transport
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ATP13A3 is involved in polyamine transportand CHO-MG models presented a similar sensitivity toward
SPD or SPM toxicity (Fig. S2, A–B). Although these data
indicate that ATP13A2 deficiency is most likely not involved in
the CHO-MG phenotype, we further investigated if ATP13A2
overexpression may partially convert the CHO-MG phenotype
to a CHO-WT phenotype. We, therefore, generated stable
CHO-WT and CHO-MG cells overexpressing comparable
levels of WT ATP13A2 (A2-WT) or a catalytically dead
mutant (D508N; A2-DN) (Fig. S6A) and observed that not only
ATP13A3 (Fig. 3B) but also ATP13A2 rescued BODIPY–PUT
uptake to comparable levels as CHO-WT (Fig. S6B). Yet,
ATP13A2 could not recover the resistance to MGBG-induced
toxicity (Fig. S6C). Moreover, unlike ATP13A3 (Fig. 5B), a
competition was not observed between MGBG and PUT in
CHO-MG cells overexpressing WT ATP13A2 (Fig. S6D),
suggesting that the human ATP13A2 isoform is not sensitive
to MGBG.
Discussion
In this study, we identified the orphan P5B-ATPase,
ATP13A3, as a major factor in the mammalian PTS that is
responsible for the polyamine-transport deficiency phenotype
of CHO-MG cells, a frequently used model to characterize the
mammalian PTS and polyamine transport inhibitors with
therapeutic potential (19–22).
Via genome sequencing in CHO-MG cells, we identified
two heterozygous mutations in the coding sequence of the
ATP13A3 gene. Both mutations are most likely located in
trans, affecting the two alleles of the ATP13A3 gene, because
our proteomics analysis indicated that the ATP13A3 protein is
lost in CHO-MG as compared with CHO-WT. One DNA
mutation causes an early truncation at the protein level that
may lead to nonsense-mediated mRNA decay and subsequent
loss of ATP13A3 mRNA and protein. Also, a frameshift mu-
tation was identified, which may result in an unstable protein
contributing to the complete loss of ATP13A3 protein. Via
complementary rescue and knockdown experiments, we
demonstrated that ATP13A3 represents a critical genetic
defect underlying the CHO-MG phenotype of polyamine up-
take deficiency. However, ATP13A3 complementation only
resulted in a partial but not full reversion of the MGBG
phenotype of CHO-MG cells. The partial recovery may indi-
cate that the human ATP13A3 isoform is not completely
compatible with the hamster ortholog. Alternatively, CHO-
MG cells were generated by random mutagenesis and several
rounds of MGBG selection (7, 13), suggesting that also mu-
tations in other genes may contribute to the MGBG resistance
phenotype. The surprisingly high endocytosis rate in CHO-
MG cells may indeed point to other genetic alterations or
compensatory responses that contribute to the phenotype.bar = 5 μm) of BODIPY–PUT in CHO-WT ± BV and CHO-MG (C), and BODIPY
BODIPY–PUT, represented in panel C, was quantified by measuring the mean flu
BODIPY–PUT = 29 images; CHO-WT BODIPY–PUT + BV = 39 images; CHO-MG B
markers, demonstrated in panel E, was analyzed in terms of Pearson’s coeffi
images), and LAMP1 (30 images). Data represent the mean ± SD, and individua
0.01, ****p < 0.0001), generated with two-way ANOVA and Bonferroni post ho
D498N; A3-WT, overexpression of WT ATP13A3; BODIPY, boron dipyrromethen
associated membrane protein 1; PUT, putrescine; RAB7/11, ras-associated bindCHO-MG cells represent one of the most frequently studied
mammalian cell models with a deficient PTS. Because WT
ATP13A3, but not a transport-deficient mutant, rescues the
polyamine uptake deficiency in CHO-MG cells, we convinc-
ingly demonstrate that the orphan P5B-ATPase ATP13A3 is a
major component of the mammalian PTS. In the evolution of
the vertebrate lineage, ATP13A3 emerged together with
ATP13A2 as the result of early gene duplication of an ancestral
P5B-ATPase ortholog (29). Via an extensive biochemical
analysis on purified protein, we recently demonstrated that
ATP13A2 is a polyamine transporter that regulates cellular
polyamine uptake (28). ATP13A2 shares with ATP13A3 a
highly conserved putative substrate-binding site in trans-
membrane segment M4 that in ATP13A2 impacts on poly-
amine transport (28, 36), indicating that also ATP13A3 may
most likely be a polyamine transporter. Here, we found that
ATP13A3 contributes to cellular polyamine uptake via a two-
step uptake mechanism, first involving endocytosis followed by
ATP13A3-mediated transport of endocytosed polyamines to
the cytosol. A two-step cellular uptake mechanism has already
been described for SPM involving endocytosis via heparan
sulfate proteoglycans (15) and lysosomal export via ATP13A2
(28). The lower fluorescent intensity of BODIPY–PUT in
CHO-MG versus CHO-WT cells may suggest that a fraction of
the endocytosed BODIPY–PUT in ATP13A3-deficient CHO-
MG cells is secreted via the recycling endosomes, the
compartment where ATP13A3 resides (29). Alternatively, the
saturation of luminal polyamines in the endosomal system of
CHO-MG cells may reduce the level of free plasma
membrane–localized polyamine receptors that capture poly-
amines before endocytosis, such as glypicans, which bind SPM
with high affinity (15).
Our data suggest that ATP13A2 and ATP13A3 fulfill
overlapping functions in cellular polyamine uptake, but only
ATP13A3 mediates MGBG sensitivity. It is also possible that
the human and hamster ATP13A2 isoforms present different
sensitivities to MGBG. The fact that two ubiquitous P5B
transporters, ATP13A2 and ATP13A3, contribute to cellular
polyamine uptake may explain why the identification of the
mammalian PTS has been challenging despite serious at-
tempts. Also, ATP13A4 and ATP13A5 are closely related
isoforms that may represent additional members of the PTS
but display a more restricted tissue and cell-type expression
(29). Future studies will address the complementarity and
redundancy of these various transporters and their interplay
with polyamine metabolism, which is under the control of
antizyme and antizyme inhibitors (37).
Studying ATP13A3 in combination with other related
P5B-ATPases will open the door to better understand the
role of polyamine uptake and transport in a broad range of–PUT colocalization with endosomal markers in CHO-MG (E) are shown. D,
orescence intensities (MFI) of BODIPY normalized to that of DAPI (CHO-WT +
ODIPY–PUT = 25 images). F, colocalization of BODIPY–PUT with endosomal
cient of BODIPY–PUT with EEA1 (49 images), RAB11 (30 images), RAB7 (29
l data points (representing replicates) are overlaid on bar graph plots (**p <
c corrections. A3-DN, overexpression of ATP13A3 catalytically dead mutant
e; BV, benzyl viologen; EEA1, early endosomal antigen 1; LAMP1, lysosomal-
ing protein 7/11.
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ATP13A3 is involved in polyamine transportpolyamine-dependent cell functions (1, 2) and the regulation
of the life span of model organisms, such as mice,
Drosophila melanogaster, Caenorhabditis elegans, and
Saccharomyces cerevisiae (3, 4). Conversely, blocking the
PTS has been proposed for cancer therapy (12, 38), and
insights into the role of P5B-ATPases in cellular polyamine
uptake will now facilitate a more targeted drug discovery
strategy. ATP13A3 expression has been highlighted as a
potential biomarker for DFMO-based therapies in pancre-
atic cancers (39), suggesting that ATP13A3 may be a
possible cancer target. Moreover, heterozygous ATP13A3
mutations have been identified in pulmonary arterial hy-
pertension (40–42). Our study suggests that altered poly-
amine transport or uptake may play a role in this rare but
fatal disorder. Strikingly, ATP13A2 mutations are not
implicated in cardiovascular but in neurodegenerative dis-
eases, such as Parkinson’s disease (43, 44), indicating that
ATP13A2 and ATP13A3 exert distinct (patho) physiological
roles. Indeed, although both isoforms are ubiquitously
expressed, slight differences were observed in substrate
specificity between ATP13A2 and ATP13A3, and also their
intracellular localization is confined to distinct sub-
compartments of the endocytic pathway (ATP13A2 in late
endosomal/lysosomes and ATP13A3 in early and recycling
endosomes) (29). Sequence differences in key regulatory
domains further indicate that both isoforms may be differ-
entially controlled by distinct signaling pathways (29, 45).
Further biochemical experiments on purified protein are
needed to conclusively confirm the putative polyamine
transport function of ATP13A3 and compare the relative
substrate specificity and regulatory mechanisms of
ATP13A3 versus ATP13A2.
Compelling evidence has shown the involvement of the
ATP13A2 transport activity, as well as its yeast P5B ortholog,
YPK9, in the homeostasis of heavy metal ions such as Zn2+,
Mn2+, and Fe3+ (46–49). However, biochemical experiments
showed that ATP13A2 is a polyamine transporter (28) and that
in vitro ATP13A2 activity is not regulated by Zn2+, Mn2+, and
Fe3+ (28, 45). The effect of P5B ATPases on heavy metal
toxicity may, therefore, be an indirect effect that requires the
polyamine transport function. Polyamines are heavy metal-
chelating agents and exert potent antioxidant effects, which
may explain why P5B polyamine transporters provide protec-
tion against heavy metal toxicity (50, 51). Further studies are
required to examine whether also ATP13A3 exerts a protective
effect against heavy metals.
In conclusion, by investigating the molecular defects in a
widely used cell model with polyamine transport deficiency, we
have identified the orphan P5B-ATPase, ATP13A3, as a novel
member of the enigmatic mammalian PTS that contributes to
cellular polyamine uptake and that is implicated in disease.Experimental procedures
Materials
We were kindly supplied with MGBG by Prof. Paul van
Veldhoven (KU Leuven, Belgium) and BODIPY-conjugated10 J. Biol. Chem. (2021) 296 100182polyamines (SPD and SPM) by Prof. Steven Verhelst (KU
Leuven, Belgium) (30).
Treatments purchased from Sigma are BV (#271845),
DFMO (#D193), Dynasore (#D7693), Pitstop-2 (#SML1169),
PUT (#P7505), SPM (#S3256), and SPD (#S2626). Alexa647-
transferrin (#T23366) was obtained from Invitrogen and gen-
istein (#ab120112) from Abcam.
Primary antibodies used were ATP13A2 (#A3361, Sigma),
ATP13A3 (#HPA029471, Sigma), early endosomal antigen 1
(EEA1; #E4156, Sigma), GAPDH (#G8795, Sigma), lysosomal-
associated membrane protein 1 (LAMP1; #ab24170, Abcam),
ras-associated binding protein 7 (RAB7; #ab137029, Abcam),
and RAB11 (#71–5300, Thermo Fisher), and secondary anti-
bodies included anti-mouse IgG (#7076S, Cell Signaling
Technology) and anti-rabbit IgG (#7074S, Cell Signaling
Technology) horseradish peroxidase–linked antibodies, and
Alexa Fluor 594 goat anti-rabbit antibody (#A-11037, Thermo
Scientific).
All unlabeled and BODIPY-labeled polyamines (PUT, SPD,
and SPM) were prepared in 0.1 M Mops-KOH (pH 7.0) to a
final stock concentration of 500 mM (200 mM in the case of
unlabeled SPM). DFMO was prepared fresh in a cell culture
media to a final stock concentration of 500 mM, and MGBG
was dissolved in Milli-Q water to a final stock concentration
of 100 mM. The endocytosis inhibitors, Dynasore, genistein,
and Pitstop-2, were dissolved in dimethyl sulfoxide (#276855,
Sigma) to final concentrations of 50 mM, 25 mM, 25 mM,
and 10 mg/ml, respectively.
Information about other reagents and kits is mentioned
when used throughout this section.Cell culture and lentiviral transduction
CHO-MG cells were generously provided by Prof. Wayne
Flintoff (University of Western Ontario, Canada), and CHO-
WT cells were used as a corresponding control. CHO-WT
and CHO-MG cells were cultured, respectively, in Ham’s
Nutrient Mixture F12 (supplemented with 5% Eagle’s mini-
mum essential medium nonessential amino acid solution;
#M7145, Sigma) and RPMI1640 media (supplemented with
2 μg/ml L-proline; #P5607, Sigma) containing 10% fetal bovine
serum (FBS; # F7524, Sigma), 10% GlutaMAX (#35050-038,
Gibco), and 1% penicillin/streptomycin (#P4458, Sigma) at
37 C with 5% CO2.
Both of the CHO-WT and CHO-MG cell lines were
authenticated via DNA fingerprinting (Leibniz-Institut
DSMZ-Deutsche Sammlung von Mikroorganismen und Zell-
kulturen GmbH).
Lentiviral transduction of CHO-WT/MG cells was carried
out using a lentiviral vector of human ATP13A2 or ATP13A3
to induce overexpression and miRNA-based short hairpin
RNA of human ATP13A3 to induce knockdown (52). The
protein expression of WT ATP13A2 (A2-WT) or ATP13A3
(A3-WT) and catalytically dead mutants, D508N of ATP13A2
(A2-DN) or D498N of ATP13A3 (A3-DN), in the stable CHO-
WT/MG cell lines was verified by immunoblotting, and the
knockdown was verified by quantitative RT-PCR.
Table 1
Gene accession numbers and primer sequences











a Primer sequence was taken from (53).
ATP13A3 is involved in polyamine transportAll cell lines used were checked for Mycoplasma contami-
nation using PlasmoTest Mycoplasma Detection kit (Inviv-
oGen) and were shown to be negative.
Cellular viability assay
Cells were cultured in a 96-well plate at a density of 1 ×
104 cells per well, except for DFMO experiments for which 5 ×
103 cells per well were seeded. The media were discarded the
next day and replaced with media containing different con-
centrations of the treatment of interest. Cell viability was
assessed after 24 h, and after 72 h for DFMO treatments using
the CellTiter 96 AQueous One Solution Cell Proliferation Assay
(MTS) (#G3580, Promega) following the manufacturer in-
structions. Absorbance was assessed at 490 nm using a plate
reader (Molecular Devices).
Cellular polyamine uptake, competition assays, and
endocytosis
Cells were cultured in a 12-well plate at a density of 3 ×
105 cells per well and were treated the next day for 90 min
at 37 C with 5-μM BODIPY-conjugated polyamine for
uptake assays and cotreated with indicated concentrations
of MGBG or nonfluorescent polyamine for competition
assays, with or without 90 min of 1-mM BV before treat-
ment to inhibit polyamine uptake. To study endocytosis,
cells were cultured in a 12-well plate at a density of 1 ×
105 cells per well. After 48 h, cells were treated with BV or
endocytosis inhibitors (100-μM Dynasore, 50-μM genistein,
and 50-μM Pitstop-2), while being starved for 30 min.
Then, they were incubated at 4 C for 15 min, treated with
Alexa647-transferrin for 20 min, and incubated at 37 C,
5% CO2 for 15 min. After incubating the cells with the
treatments, they were washed with Dulbecco’s PBS (DPBS)
modified with no calcium or magnesium (#D8537, Sigma)
and collected using TrypLE Express (#12604021, Thermo
Fisher) or trypsin in case of Alexa647-transferrin experi-
ments. Cells were resuspended in DPBS supplemented with
1% bovine serum albumin (BSA; #3854.3, Carl Roth), and
uptake was measured using an Attune NxT Flow Cytometer
(Life Technologies). The settings were set at 1 × 104 events
(debris free) per condition, and the values of the mean
fluorescent intensity of the blue laser channel (BL1; exci-
tation = 488 nm, emission = 530 nm), with BODIPY–PUT/
SPD/SPM, and the red laser channel (RL1; excitation =
637 nm, emission = 670 nm), with Alexa647-transferrin,
were used for further analysis.Confocal microscopy
Cells were seeded in 12-well plates at a density of 5 ×
103 cells per well on coverslips, and they were left to grow for
2 days after the seeding. They were then treated with
BODIPY–PUT for 90 min at 37 C with or without 30-min
pretreatment of 1-mM BV. Afterward, cells were washed
with DPBS, fixed with 4% paraformaldehyde for 30 min at
37 C, and washed again with DPBS. This was followed byeither storing the cells in DPBS at 4 C or directly proceeding
further. First, cells were permeabilized for 30 min with 0.1%
Triton X prepared in DPBS containing 0.1% Tween 20 (DPBS-
T). Then, they were blocked for 60 min with 0.1 M glycine in
DPBS-T and blocked further for 60 min with DPBS-T con-
taining 10% FBS and 1% BSA. Subsequently, cells were incu-
bated overnight at 4 C with specific primary antibodies for
EEA1, RAB11, RAB7, and LAMP1 (1:200 in DPBS-T with 1%
FBS and 0.1% BSA). Then, cells were briefly blocked again for
15 min with DPBS-T containing 10% FBS and 1% BSA. Im-
munostaining was carried out with Alexa Fluor 594 goat anti-
rabbit antibody (1:1000 in DPBS-T with 1% FBS and 0.1%
BSA) for 60 min followed by nuclear staining using 4’,6-
diamidino-2-phenylindole (DAPI; #D9542, Sigma; 200 ng/ml
in DPBS-T with 1% FBS and 0.1% BSA) for 15 min. Eventually,
cells were washed thoroughly with DPBS-T, and coverslips
were glued on glass slides using FluorSave reagent
(#345789–20 ml, Millipore), left to dry, and then stored
at −20 C till imaging. Images were acquired using an LSM780
confocal microscope (Zeiss) using a 63x objective lens. Ana-
lyses for mean fluorescent intensity and Pearson’s coefficient
for colocalization were performed using Fiji/ImageJ.
Primer design, RNA extraction, and quantitative RT PCR
Primers were designed using Primer-BLAST or Primer3.
BLAT was used to identify the target chromosome of the
primers, exon-spanning was checked using Ensembl, and
primers were synthesized by Integrated DNA Technologies.
Primer sequences are displayed in Table 1. FKBP prolyl
isomerase 1A (FKBP1A) was used as a reference gene (53).
Standard curves from 5-fold serial dilutions of cDNA were
used to determine amplification efficiencies. Primer specificity
and validation were verified by analyzing the PCR product on
an agarose gel in comparison with the Low Molecular Weight
DNA Ladder (N3233S, New England Biolabs).
RNA was isolated from 5 × 106 cells per cell line using
NucleoSpin RNA plus Kit (#740984, Macherey-Nagel). RNA
from the hamsters’ brains was extracted using TRIzol reagent
(#15596026 & 15596018, Invitrogen) following the manufac-
turer’s instructions. The concentration and purity (260:230 nm
and 260:280 nm absorbance ratios) were measured using a
Nanodrop spectrophotometer (Thermo Fisher).
Conversion of 1 μg of RNA to cDNA was performed using
RevertAid H Minus First Strand cDNA Synthesis Kit (#K1631,J. Biol. Chem. (2021) 296 100182 11
ATP13A3 is involved in polyamine transportThermo Fisher). Five-fold serial dilutions of cDNA were
checked in duplicates. Reaction mixtures contained 12.5-μl
SYBR Green master mix (#04707516001, Roche), 1-μl forward
primer, 1-μl reverse primer, 5.5-μl distilled water, and 5-μl
cDNA, whereas the negative controls were prepared using
an equivalent volume of distilled water instead of cDNA. Re-
actions were performed in a 96-well plate using LightCycler
machine (Roche), and amplification conditions were as follows:
95 C for 10 min followed by 50 cycles at 95 C for 10 s and
55 C for 30 s, and the reaction was terminated at 95 C for
1 min and then at 55 C for 1 min followed by melting curve
analysis from 55 to 95 C. The mean Cq values were analyzed.
Immunoblotting
Cells were detached using TrypLE Express, and then they
were centrifuged at 300g for 5 min and washed once with
DPBS and then centrifuged again. Total cell lysates were
obtained by lysing the final pellets in RIPA buffer (#89900,
Thermo Fisher) containing 10x protease (#S8830, Sigma)
and 1x phosphatase (#A32957, Thermo Fisher) inhibitors.
Protein concentration was determined using Pierce BCA
Protein Assay Kit (#23227, Thermo Fisher) following the
manufacturer’s instructions. Immunoblotting was per-
formed as described (47). Primary antibodies against
ATP13A2 (1:1000), ATP13A3 (1:1000), and GAPDH
(1:5000) were incubated overnight. Anti-mouse IgG and
anti-rabbit IgG horseradish peroxidase–linked secondary
antibodies were used for 1 h at a dilution of 1:2000. Detec-
tion was performed using SuperSignal West Pico PLUS
Chemiluminescent Substrate (#34580, Thermo Fisher) or
SuperSignal West Femto Maximum Sensitivity Substrate
(#34095, Thermo Fisher), and visualization was carried out
using the Bio-Rad ChemiDoc MP imaging system.
Synthesis of BODIPY-conjugated PUT
All starting materials and solvents were bought from com-
mercial vendors and used without further purification. Re-
actions were analyzed by TLC on precoated 0.20-mm-thick
ALUGRAM TLC sheets with fluorescent indicator and by LC-
MS performed on a Prominence Ultrafast Liquid Chroma-
tography system (Shimadzu) equipped with a 2 × 150 mm C18
analytical column (Waters X-Bridge) coupled to an MS-2020
single quadrupole mass analyzer (Shimadzu). A linear
gradient of 5 to 80% acetonitrile in water (with 0.1% formic
acid [FA]) was utilized. Silica column chromatography was
performed using 230 to 400 mesh silica (Kieselgel 60). NMR
spectra were recorded in CDCl3 and measured using a Bruker
Ultrashield 400 MHz NMR Spectrometer. Chemical shifts are




NH212 J. Biol. Chem. (2021) 296 100182Boc-protected PUT 1 was synthesized based on the method
of Dardonville et al. (54). To this end, PUT (323 mg, 4 eq.,
3.67 mmol) was dissolved in 4-ml CHCl3 and cooled to 0 C.
Boc2O (526 μl, 1eq., 2.29 mmol) was dissolved in 10-ml CHCl3
and slowly added to the PUT solution over the course of 2 h.
The reaction mixture was then allowed to warm to RT and
stirred overnight. Upon completion of the reaction (TLC: PE/
EtOAC 1:1), the solvents were evaporated and the crude
product was redissolved in 20-ml dichloromethane (DCM).
The crude mixture was extracted three times with water. The
organic fraction was collected, dried over MgSO4, and
concentrated. The product was further purified using column
chromatography (petroleum ether/EA 1:1 → EA/MeOH/TEA
9:1:0.01) to obtain the title compound as a colorless oil.
(169 mg, yield = 98%) electrospray ionization-mass spec-
trometry (ESI-MS): m/z calculated for C9H20N2O2 [M + H]
+
requires 189.15, found 188.953-Azidopropyl 4-methylbenzenesulfonate (2)
TsO N3
Tosylate 2 was synthesized based on the procedure of
Chan et al. (55). To this end, 3-chloropropanol (1.00 g,
10.58 mmol, 1 eq.) was dissolved in 10-ml water. NaN3
(688 mg, 10.58 mmol, 1 eq.) was added to this solution, and
the reaction was refluxed overnight. Upon completion of the
reaction (petroleum ether/EA 1:1), the reaction mixture was
cooled to RT and extracted three times with 20-ml DCM.
The organic fractions were collected, dried over MgSO4,
and evaporated to dryness. The crude product was redis-
solved in 15-ml dry DCM. Triethylamine (2.95 ml, 2 eq.,
21.17 mmol) was added, and the mixture was cooled to 0 C.
Tosyl chloride (2.44 g, 1.2 eq., 11.64 mmol) was added to the
reaction mixture, which was subsequently allowed to warm to
RT and stirred overnight. Upon completion of the reaction
(TLC: PE:EtOAc 4:1), the solvents were evaporated and the
crude product purified by column chromatography (PE:E-
tOAC 1:0 → 9:1) to obtain the title compound as a colorless
solid. (1.554 g, yield = 58% over two steps) ESI-MS: m/z
calculated for C10H13N3O3S [M + H]






Boc-PUT 1 (88 mg, 467 μmol, 1 eq.) was dissolved in 2-ml
dry tetrahydrofuran under argon atmosphere. Diisopropyle-
thylamine (333 μl, 1.87 mmol, 4 eq.) was added to this solution,
which was subsequently cooled to 0 C. Tosylate 2 was added
ATP13A3 is involved in polyamine transportgradually to the reaction, which was subsequently allowed to
warm up to RT. The reaction mixture was stirred overnight at
RT. Upon completion of the reaction (TLC: DCM/MeOH 9:1),
the solvents were evaporated and the crude product purified
over column chromatography (DCM/MeOH 9:1) to obtain the
title compound as a colorless oil. (38.37 mg yield = 30%) ESI-








Alkyne–BODIPY 4 was synthesized according to the
method described in Vanhoutte et al. (30). The identity was in
agreement with the data reported in the literature. ESI-MS: m/
z calculated for C18H21BF2N2 [M + H]




Compound 3 (24 mg, 1 eq., 88.44 μmol) was dissolved in 2-
ml DCM. Alkyne–BODIPY 4 (29.18 mg, 1.05 eq., 92.86 μmol),
diisopropylethylamine (63 μl, 4 eq., 353.77 μmol), and subse-
quently CuBr (6.34 mg, 0.5 eq., 44.22 μmol) were added to the
reaction mixture. The reaction was stirred at RT for 3 h. Upon
completion of the reaction (TLC: DCM/MeOH 9:1), the sol-
vents were evaporated and the crude product purified using
column chromatography (DCM/MeOH 9:1) to obtain the title






Compound 5 (32.45 mg, 55.42 μmol) was dissolved in 6-ml
4N HCl in dioxane and stirred for 5 min at RT. Upon
completion of the reaction, the solvents were evaporated to
obtain the title compound as a red solid (30.94 mg, yield =
100%). ESI-MS: m/z calculated for C25H40BCl2F2N7 [M+H-
HCl]+ requires 486.32, found 486.15. 1H NMR (400 MHz,
CDCl3, 298K): δ = 7.91 to 7.48 (m, 2H), 7.24 to 6.94 (m, 1H),
6.44 to 5.66 (m, 2H), 3.83 to 3.53 (m, 4H), 3.22 to 3.00 (m, 4H),
2.71 to 1.81 (m, 8H), 1.63 to 1.32 (m, 14H).
Proteomics
Sample preparation and LC-MS/MS analysis
A count of 5 × 106 trypsinized cells per cell line was
collected by two centrifugation spins at 300g for 5 min, fol-
lowed by pellet resuspension in DPBS. Dry pellets were snap-
frozen in liquid nitrogen and stored at −80 C. Proteomics was
performed on four biological replicates of each cell line.
A total of 8 membrane fraction samples were prepared for
LC-MS/MS analysis. Sample preparation was based on
methods reported earlier by Ning et al. in 2013 and 2014
(56, 57). For this purpose, 500 μl of a 100-mM Hepes solution
was added to samples containing 100-μg protein in 500-μl
0.25 M sucrose and protease inhibitors to reach a final Hepes
concentration of 50 mM. Amphipol (APols) A8-35 (Anatrace
Products) was added to a final concentration of 1%. Samples
were homogenized on ice by using a tip sonicator (VC100
Vibra-Cell, Sonics & Materials) using the following settings:
40-Hz amplitude, 5 s ON, 2 s OFF, 3 cycles, 7 to 9 W output.
After sonication, samples were incubated at RT with shaking
(650 rpm) for 10 min. Reduction of sample protein disulfide
bonds was achieved by adding DTT (dithiothreitol, Sigma
Aldrich) to a final concentration of 5 mM and incubation for
30 min at 50 C and 650 rpm. Alkylation was performed by
adding iodoacetamide (Fluka) to a final concentration of
10 mM and incubation at RT in the dark for 15 min atJ. Biol. Chem. (2021) 296 100182 13
ATP13A3 is involved in polyamine transport650 rpm. After reduction and alkylation, the pH was adjusted
with 10% formic acid (FA; Acros Organics) to a final con-
centration of 1% FA and samples incubated for 10 min at RT
and 500 rpm. APols were precipitated by centrifugation at
16,000g for 5 min at RT and the supernatant discarded. The
APols pellet was washed with 0.1% FA for 5 min at 500 rpm
and precipitated again by centrifugation at 16,000g for 5 min at
RT. The supernatant was again discarded, and the pellet was
solubilized in 200 μl of 100-mM tetraethylammonium bicar-
bonate (Sigma Aldrich). One microgram of trypsin was added
to each sample, and digestion was performed overnight at 37
C and 800 rpm shaking. Samples were briefly spun down, and
the pH adjusted to a final FA concentration of 1% and incu-
bated for 10 min at RT at 650 rpm. APols were precipitated by
centrifugation at 16,000g for 10 min at RT, and the superna-
tant, containing the tryptic peptides, was transferred to MS
vials and vacuum-dried completely. Samples were stored
at −20 C until measured by LC-MS/MS.
Purified peptides were redissolved in a 30-μl loading solvent
(0.1% trifluoroacetic acid in water/acetonitrile (96:4, v/v)), and
the peptide concentration was determined by measuring on a
Lunatic spectrophotometer (Unchained Labs) (Mendes Maia
et al. 2020 ACS Omega, in press). 2 μg of peptide material of
each sample was injected for LC-MS/MS analysis on an Ulti-
mate 3000 RSLC nano-LC (Thermo Fisher Scientific, Bremen,
Germany) in-line connected to a Q Exactive HF mass spec-
trometer (Thermo Fisher Scientific) equipped with a nano-
spray flex ion source (Thermo Fisher Scientific).
Trapping was performed at 10 μl/min for 4 min in loading
solvent A on a 20-mm trapping column (made in-house,
100-μm internal diameter, 5-μm beads, C18 Reprosil-HD, Dr
Maisch, Germany). Peptide separation after trapping was
performed on a 200-cm-long micropillar array column
(PharmaFluidics) with C18-endcapped functionality. The
Ultimate 3000’s column oven was set to 50 C. For proper
ionization, a fused silica PicoTip emitter (10-μm inner diam-
eter) (New Objective) was connected to the μPAC outlet union
and a grounded connection was provided to this union.
Peptides were eluted by a nonlinear gradient from 1 to 55% MS
solvent B (0.1% FA in water/acetonitrile (2:8, v/v)) over
145 min, starting at a flow rate of 750 nl/min switching to
300 nl/min after 15 min, followed by a 15-min washing phase
plateauing at 99% MS solvent B. Re-equilibration with 99% MS
solvent A (0.1% FA in water) was performed at 300 nl/min for
45 min followed by 5 min at 750 nl/min adding up to a total
run length of 210 min. The mass spectrometer was operated in
a data-dependent, positive ionization mode, automatically
switching between MS and MS/MS acquisition for the 16 most
abundant peaks in a given MS spectrum. The source voltage
was 2.2 kV, and the capillary temperature was 275 C. One
MS1 scan (m/z 375–1,500, AGC target 3 × 106 ions, maximum
ion injection time 60 ms), acquired at a resolution of 60,000 (at
200 m/z), was followed by up to 16 tandem MS scans (reso-
lution 15,000 at 200 m/z) of the most intense ions fulfilling
predefined selection criteria (AGC target 1 × 105 ions,
maximum ion injection time 80 ms, isolation window 1.5 Da,
fixed first mass 145 m/z, spectrum data type: centroid,14 J. Biol. Chem. (2021) 296 100182intensity threshold 1.3 × 104, exclusion of unassigned, 1, 7, 8,
>8 positively charged precursors, peptide match preferred,
exclude isotopes on, dynamic exclusion time 12 s). The higher-
energy collisional dissociation was set to 28% normalized
collision energy, and the polydimethylcyclosiloxane back-
ground ion at 445.12003 Da was used for internal calibration
(lock mass).
Data analysis
Data analysis was performed with MaxQuant (version
1.6.9.0) using the Andromeda search engine with default
search settings including a false discovery rate (FDR) set at 1%
on both the peptide and protein level (58, 59). Spectra were
searched against the Chinese hamster (CHO K1 cell line)
Swiss-Prot database (from September 2019 with 23,889 en-
tries) and NCBI single protein databases for hamster
ATP13A1, ATP13A2, ATP13A3, and ATP13A4. The mass
tolerance for precursor and fragment ions was set to 4.5 and
20 ppm, respectively, during the main search. Enzyme speci-
ficity was set to the C-terminal of arginine and lysine, also
allowing cleavage next to prolines with a maximum of two
missed cleavages. Variable modifications were set to oxidation
of methionine residues and acetylation of protein N-termini.
Matching between runs was enabled with a matching time
window of 0.7 min and an alignment time window of 20 min.
Only proteins with at least one unique or razor peptide were
retained, leading to the identification of 5040 proteins. Pro-
teins were quantified by the MaxLFQ algorithm integrated into
the MaxQuant software. A minimum ratio count of two
unique or razor peptides was required for quantification.
Further data analysis was performed with the Perseus software
(version 1.6.7.0) after uploading the protein groups file from
MaxQuant (60). Reverse database hits were removed, and
replicate samples were grouped. Proteins with less than three
valid values in at least one group were removed, and missing
values were imputed from a normal distribution around the
detection limit resulting in 3382 quantified proteins, which
were subsequently used for further data analysis. These
quantified proteins were subjected to a two-sided, unpaired
t-test using permutation-based multiparameter correction
with 1000 randomizations and an FDR of 1%. The results of
this t-test are shown in the volcano plot in Fig. S2B. For each
protein, the log2 (MG/WT) fold change value is indicated on
the X-axis, whereas the statistical significance (-log p-value) is
indicated on the Y-axis. Proteins outside the curved lines, set
by an FDR value of 0.01 and an S0 value of 0.1 in the Perseus
software, represent specific significant upregulated or down-
regulated proteins.Genomics
Samples were prepared with the KAPA Library HyperPrep
Kit (#07962363001, Roche) according to the manufacturer
protocol. Samples were indexed to allow for multiplexing and
subsequently sequenced on an Illumina NovaSeq platform
according to the manufacturer recommendations. Paired-end
reads of 150-bp length were produced with a total of 59 M
ATP13A3 is involved in polyamine transportreads. Quality control of raw reads was performed with
FastQC, v0.11.7 (61). Alignment was performed with Bur-
rows–Wheeler aligner maximum exact matches software (62)
against the Chinese Hamster reference genome. Reads map-
ping to multiple loci in the reference genome were discarded.
Resulting binary alignment map files were handled with
SAMtools, v1.5 (63). Validation of binary alignment map files
and duplicate marking was performed with Picard. Variants
and VCF files were produced with GATK 3.7 (64). The effect
of variants was determined with Ensembl Variant Effect Pre-
dictor (65).
Statistical analysis
Data are presented as the mean ± SE or mean ± SD, and ‘n’
indicates the number of independent experiments. Statistical
analysis was conducted by one-/two-way ANOVA with Bon-
ferroni post hoc corrections or unpaired (Mann-Whitney)
t-test (*/€p < 0.05, **/€€p < 0.01, ***/€€€p < 0.001, and
****/€€€€p < 0.0001).
Data availability
The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE (66)
partner repository (http://www.ebi.ac.uk/pride) with the data
set identifier PXD020559 and 10.6019/PXD020559. And
the full genomics data set can be accessed on GenBank
(sequence read archive accession: PRJNA627458) via the link
https://www.ncbi.nlm.nih.gov/sra/PRJNA627458. All of the
remaining data are contained in the article or its supporting
information.
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